Features

Viewpoints

irAEs Linked to Ipilimumab Should Not Preclude Subsequent Anti–PD-1 Therapy

By

Leah Lawrence

Publish Date August 14, 2020

This retrospective study suggests that patients with prior ipilimumab-related adverse events related can safely retry anti–PD-1 therapy.

Upfront Radiation May Be a Cost-Effective Strategy in Oligorecurrent Hormone-Sensitive Prostate Cancer

By

Katarina Zimmer, MSci, MS

Publish Date July 31, 2020

Upfront metastasis-directed therapy may be a viable treatment approach in patients with oligorecurrent disease, particularly those who wish to defer systemic therapy.

From the Advisory Board

We Can Treat Hodgkin’s Lymphoma Like Melanoma?

By

Isabel Cunningham, MD

Publish Date September 3, 2015

Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.

Slideshows

BAVENCIO (avelumab) for Merkel Cell Carcinoma

IMLYGIC (talimogene laherparepvec) for Melanoma

Features

Phase 2 Trial Using IL-12 Gene Therapy for Glioblastoma Reaches Recruitment Target

By

Victoria Forster, PhD

Publish Date August 13, 2020

A new approach combining inducible gene therapy and an anti–PD-1 shows promise in hard-to-treat brain tumors.

Incorporating Immunotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia

By

Roxanne Nelson, RN, BSN

Publish Date August 13, 2020

Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.

The Twitter Effect on How Oncologists Conduct and Share Research

By

Sarah Elizabeth Richards

Publish Date August 12, 2020

The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.